Mission Statement, Vision, & Core Values of ChromaDex Corporation (CDXC)

A company's Mission Statement, Vision, and Core Values aren't just HR boilerplate; they're the engine driving the financials, especially for a bioscience leader like ChromaDex Corporation, now operating as Niagen Bioscience Inc.. When you see third-quarter 2025 revenue hit a record $34 million, a 33% jump year-over-year, you have to ask: what core principles are fueling that kind of accelerated growth?.

The company is on track for an estimated full-year 2025 revenue between $124.5 million and $129.5 million-a significant jump from 2024's $99.6 million-so are you confident that their stated commitment to 'scientific integrity and transparency' is strong enough to justify a high valuation in the longevity market?. With $64.3 million in cash and zero debt as of Q3 2025, understanding their foundational values is defintely key to mapping their future risk and opportunity, but what does their focus on Nicotinamide Adenine Dinucleotide (NAD+) research really mean for the long-term investor?.

ChromaDex Corporation (CDXC) Overview

You're looking for a clear picture of ChromaDex Corporation, a bioscience firm that's defintely made its mark in the healthy aging space. The direct takeaway is this: the company, which officially changed its name to Niagen Bioscience, Inc. (NAGE) in March 2025, is the global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and is projecting strong revenue growth for the full 2025 fiscal year, building on a profitable 2024.

ChromaDex Corporation, founded in 1999, is rooted in analytical chemistry but pivoted significantly by acquiring the exclusive rights to commercialize Niagen (nicotinamide riboside or NR) in 2011. Niagen is a patented form of vitamin B3 that acts as a precursor to NAD+, a vital coenzyme that declines with age. Their business model centers on discovering, developing, and commercializing science-backed ingredients, with revenue coming from three main segments:

• Consumer products like their flagship supplement, Tru Niagen.
• Proprietary ingredient sales, including food-grade and pharmaceutical-grade Niagen.
• Analytical reference standards and services.

The company is projecting total net sales for the full 2025 fiscal year to reach approximately $117.5 million, a roughly 18% jump from the $99.6 million reported for the full year 2024. This growth shows the market's increasing acceptance of science-backed longevity products. If you want to dive deeper into the company's foundation, you can check out ChromaDex Corporation (CDXC): History, Ownership, Mission, How It Works & Makes Money.

Here's the quick math on their recent performance: they ended 2024 with a net income of $8.6 million and a strong cash position of $44.7 million with no debt, which gives them a lot of flexibility to seize new opportunities.

Record-Breaking Q3 2025 Financial Performance

The latest financial reports, specifically the third quarter of 2025, underscore the company's accelerating growth trajectory. Total net sales for Q3 2025 increased a substantial 33% year-over-year to $34.0 million. This isn't just a slight bump; it's a clear signal that their focus on core products is paying off, especially in e-commerce.

The main driver of this record revenue was the flagship consumer product, Tru Niagen. Sales of Tru Niagen surged by 44% to $26.0 million in the third quarter of 2025. This shows that consumers are increasingly prioritizing cellular health. Also, the gross margin improved to 64.5%, up 100 basis points from the prior year, reflecting better product mix and supply chain efficiency. This margin expansion is crucial for sustainable profitability.

The bottom line also saw significant improvement, with net income hitting $4.6 million for the quarter. This consistent profitability, coupled with the expansion of their pharmaceutical-grade Niagen ingredient business-including the launch of Niagen IV and injections-demonstrates a strong, diversified growth engine. They are executing well against their plan, but still need to manage the cost of brand expansion to maintain this margin growth.

ChromaDex: A Leader in NAD+ Science

ChromaDex Corporation has cemented its position as a clear leader in the healthy aging and nutraceutical industries, largely by being the 'global authority' on NAD+ research. They don't just sell a supplement; they sell an ingredient-Niagen-that is backed by a robust portfolio of patents and extensive, peer-reviewed clinical research. This scientific rigor sets the company apart in a crowded supplement market.

The company's commitment to science has resulted in its flagship product, Tru Niagen, being recognized as the number one healthy-aging NAD+ supplement in the United States by revenue on the largest U.S. e-commerce marketplace. Furthermore, the company was named to the Inc. 2024 Best in Business List in the Health Products Category, which recognizes companies making a significant impact on their industries. This market leadership is protected by its comprehensive intellectual property portfolio, which safeguards Niagen and other NAD+ precursors. Their success is a direct result of their science-first approach. To understand the full scope of their market dominance and why they are so successful, you need to look at the science and the business model in detail.

ChromaDex Corporation (CDXC) Mission Statement

You're looking for the bedrock of a company's long-term value, and honestly, it starts with the mission. For ChromaDex Corporation (CDXC)-now operating as Niagen Bioscience, Inc., ticker NAGE, as of March 2025-the mission isn't just a marketing line; it's a clear directive that guides their entire strategy, from R&D spend to supply chain integrity. Their core purpose is to improve healthspan by restoring and optimizing NAD+ levels, empowering people to live healthier and more vibrant lives as they age. This focus on cellular health is what drove their net income to a strong $4.6 million in Q3 2025 alone.

The mission's significance is simple: it defines the company's competitive moat and its commitment to the consumer. It's why they invest heavily in proprietary ingredients like Niagen® (nicotinamide riboside, or NR), a novel form of vitamin B3 that boosts Nicotinamide Adenine Dinucleotide (NAD+), a vital coenzyme for cellular energy. This isn't about selling a quick fix; it's about pioneering a new frontier in healthy aging. For more on the market dynamics, you should be Exploring ChromaDex Corporation (CDXC) Investor Profile: Who's Buying and Why?

Pioneering NAD+ Science and Research

The first pillar of the company's mission is an unwavering commitment to scientific rigor. They position themselves as the global authority on NAD+ science, and they back that up with real investment. This is where the rubber meets the road: you can't be a bioscience leader without the research to prove it. Here's the quick math on their scientific scale:

• Over 275 research agreements worldwide.
• More than 175 peer-reviewed publications.
• Over 30 human clinical studies on Niagen®.

This commitment means their flagship ingredient, Niagen®, is the most efficient and superior-quality NAD+ booster available, setting the benchmark for the entire industry. For example, a recent randomized controlled trial showed that Niagen NR supplementation increased NAD+ levels up to 3.1-fold after 5-10 weeks, confirming its effectiveness at a cellular level.

Empowering Healthier and More Vibrant Lives

The second core component translates the science into a tangible human benefit: improving healthspan. This is the empathetic goal of the mission-to help people age better, not just live longer. The success of this component is best measured by the growth of their consumer-facing products, particularly Tru Niagen®. The market is defintely responding.

In the first half of fiscal year 2025, the company's net sales surged 37% to $61.6 million, demonstrating that consumers are actively seeking out their science-backed solutions. Specifically, Tru Niagen® sales hit $26.0 million in Q3 2025, a massive 44% increase year-over-year, driven by strong e-commerce activity. This growth isn't accidental; it's a direct result of their mission to deliver a product clinically proven to increase NAD+ levels and support overall cellular health.

Uncompromising Scientific Integrity and Quality

Finally, the mission is grounded in a dedication to scientific integrity and transparency. In the dietary supplement world, where quality can be a minefield, this is a crucial differentiator. They hold two distinct A2LA accreditations, which is a rigorous, third-party assessment of their laboratory operations, technical competence, and quality management systems. This is a big deal for investor confidence.

Their commitment to quality is starkly revealed in their Market Surveillance Program. An analysis conducted between February 2023 and January 2025 of 39 NR products purchased in the U.S. found that only 13% of the tested supplements actually met or exceeded their label claims for NR content. By contrast, the company's gross margin expanded to a robust 64.5% in Q3 2025, reflecting a premium product mix and operational efficiency that comes from controlling the quality benchmark, from raw material to finished good. This focus on the 'gold standard' protects their brand and justifies the higher pricing of their patented ingredient, Niagen®.

ChromaDex Corporation (CDXC) Vision Statement

You're looking for the North Star guiding ChromaDex Corporation, and the vision is clear: it's about extending a person's healthy years, or what we call 'healthspan.' The core purpose is to improve healthspan by restoring and optimizing NAD+ levels, which is the foundational cellular fuel, empowering people to live healthier and more vibrant lives as they age. This isn't just about selling a supplement; it's a commitment to a longer, better quality of life.

The vision is grounded in the science of nicotinamide adenine dinucleotide (NAD+), a vital coenzyme that naturally declines as we get older or face everyday stressors. ChromaDex Corporation, which officially changed its name to Niagen Bioscience, Inc. (NAGE) in March 2025, positions itself as the global authority in this research. Their strategic focus is on making their patented ingredient, Niagen (nicotinamide riboside, or NR), the gold standard for NAD+ support across all relevant channels.

This vision directly maps to their aggressive growth strategy. For the full year 2025, the company has revised its revenue growth guidance to a significant 25% to 30% year-over-year increase. Here's the quick math: building on the $99.6 million in net sales from 2024, that puts the 2025 net sales projection in the range of roughly $124.5 million to $129.5 million. That's a defintely strong trajectory. Exploring ChromaDex Corporation (CDXC) Investor Profile: Who's Buying and Why?

Mission: Pioneering NAD+ Science with Integrity

The mission is the engine driving the vision: improving global health through innovative ingredient technologies and a dedication to scientific integrity and transparency. It's a dual mandate-innovation and rigor. This bioscience company operates by discovering, developing, and commercializing science-backed ingredients, with Niagen at the center.

A key near-term opportunity is the expansion of their pharmaceutical-grade ingredient business. The company is actively moving into the high-growth intravenous (IV) and injection market with Niagen Plus, expanding into over 1,000 wellness and healthcare clinics across the U.S. This channel is expected to grow at a much greater pace than the supplement business, which is already performing well, with Q3 2025 net sales reaching a remarkable $34 million.

But, to be fair, this mission isn't without risk. The regulatory landscape, particularly around competing compounds like NMN, presents a hurdle. Still, ChromaDex Corporation's focus on clinical validation and a robust patent portfolio for NR is their protective moat, giving them a competitive edge in the fast-growing longevity market. They are conservative in execution but aggressive in ideation.

Core Values: The Foundation for Growth

The company's core values are the non-negotiables that support their scientific authority and market position. They are built on a foundation of integrity, transparency, and scientific excellence. These values aren't just posters on a wall; they dictate how they approach everything from R&D to investor relations.

• Excellence: Set the gold standard in research.
• Integrity: Uphold uncompromising scientific standards.
• Innovation: Pioneer the future of healthy aging.
• Scientific Rigor: Back products with world-class research.
• Transparency: Maintain clear communication on product quality.

These values translate directly into financial strength and operational efficiency. For example, their commitment to operational excellence helped drive the Q3 2025 gross margin up to 64.5%, a 100-basis-point improvement from the previous year. Plus, they ended the third quarter of 2025 with $64.3 million in cash and zero debt, showcasing a strong balance sheet that allows them to maintain a steady investment in research and development to drive future innovation. That financial resilience is a direct result of their disciplined, science-first approach.

The next concrete step for you is to map these core values against the company's Q4 2025 strategic announcements, particularly any new pharmaceutical-grade Niagen applications, to see if they are continuing to deliver on their promise of scientific rigor and innovation.

ChromaDex Corporation (CDXC) Core Values

You're looking for the bedrock of ChromaDex Corporation's strategy-the mission, vision, and core values that drive their financial performance. Honestly, in the bioscience space, your values aren't just feel-good marketing; they are the risk-mitigation framework. The company's core purpose is clear: to improve healthspan by restoring and optimizing NAD+ (nicotinamide adenine dinucleotide) levels, empowering people to live healthier and more vibrant lives as they age. This focus is so central that the company, formerly ChromaDex Corporation, strategically rebranded to Niagen Bioscience in March 2025 to align its corporate identity with its flagship ingredient, Niagen (nicotinamide riboside, or NR).

This rebrand and the subsequent strategic focus have paid off. The company finished the third quarter of 2025 with a strong balance sheet, reporting a cash position of $64.3 million and zero debt, which gives them serious operational flexibility. Let's map their core values-Excellence, Integrity, Innovation, Scientific Rigor, and Transparency-to the actions driving that growth.

Scientific Rigor

Scientific Rigor is where the company earns its premium. They don't just sell supplements; they pioneer NAD+ science, and that requires constant, heavy investment in research and development. The commitment here is evident in their external research program, which has supported over 35 human clinical studies on Niagen. This is defintely a gold standard in the nutraceutical industry.

• Fund research to validate Niagen's efficacy in new applications.
• Collaborate with independent investigators from esteemed universities globally.
• Maintain a robust patent portfolio protecting NR and other NAD+ precursors.

A key example is their Market Surveillance Program, which demonstrates their commitment to scientific truth over market convenience. A comprehensive analysis conducted through their ISO 17025 accredited laboratory found that a shocking 87% of tested NR dietary supplements from competitors did not meet their label claims as of early 2025. That's a powerful, data-driven action that protects consumers and reinforces the value of their own rigorously studied ingredient. You simply cannot ignore that kind of data when evaluating the competitive landscape. If you want to dive deeper into who is betting on this scientific moat, you should be Exploring ChromaDex Corporation (CDXC) Investor Profile: Who's Buying and Why?

Integrity & Transparency

For a bioscience company, integrity is about more than just ethics; it's about quality control and clear communication with regulators and the public. This value is visibly grounded in their operations, which are backed by industry-leading standards. The company proudly holds two distinct A2LA accreditations for its laboratory operations, which is a rigorous, third-party assessment of technical competence and quality management systems. This isn't cheap or easy to maintain, but it builds trust.

Their financial integrity is also a strong indicator. The resolution of the legal dispute with Elysium Health, Inc., resulting in a $2.65 million settlement for ChromaDex Corporation in the first half of 2025, removed a major financial distraction and validated their intellectual property strategy. Clear, consistent financial reporting and a debt-free balance sheet as of Q3 2025 further signal financial integrity that investors can rely on.

Innovation & Excellence

Innovation at ChromaDex Corporation is focused on expanding Niagen's delivery and market reach beyond traditional supplements, driving top-line growth. This is where their near-term opportunity lies. The company has moved decisively into the clinical setting with the launch of pharmaceutical-grade Niagen IV and injection products.

This initiative has seen rapid expansion, with Niagen IV and injection kits available at over 1,000 wellness and healthcare clinics across the U.S. as of November 2025. That's a significant jump from the 475 clinics reported earlier in the year. The market is responding to this excellence in execution. The company's net sales outlook for the full year 2025 was revised upward to a growth of 25% to 30% year-over-year, up from an earlier projection of around 18%. This growth is fueled by their multi-channel strategy, which saw Q3 2025 revenue hit $34 million, a 33% increase year-over-year. That's a strong signal of market adoption for their innovative products.